[1]刘宗瑞,赵豪,陈艳荣,等.他汀类药物治疗对延缓慢性肾脏病进展的荟萃分析[J].南方医科大学学报,2016,(04):445.
点击复制

他汀类药物治疗对延缓慢性肾脏病进展的荟萃分析()
分享到:

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2016年04期
页码:
445
栏目:
出版日期:
2016-04-16

文章信息/Info

Title:
Effects of statins on delaying progression of chronic kidney disease: a meta-analysis
作者:
刘宗瑞赵豪陈艳荣唐冬冬牛红心
关键词:
他汀类药物慢性肾脏病终末期肾病肾小球滤过率荟萃分析
Keywords:
statins chronic kidney disease end-stage renal disease glomerular filtration rate meta-analysis
摘要:
目的评价他汀类药物治疗对非透析的慢性肾脏病患者肾脏病进展的影响。方法通过对电子数据库(时间截止2015年2 月)的检索,筛选符合纳入标准的随机对照试验,采用随机效应模型合并相关肾脏病进展指标。结果共纳入28个研究,共包括 45 688例慢性肾脏病患者。Meta分析结果显示,与对照组相比,非透析的慢性肾脏病患者接受他汀类药物治疗不能减少终末期 肾病的发生(RR=0.98,95% CI:0.91-1.05),也不能降低肌酐翻倍风险(RR 1.43,95% CI 0.26 to 7.79),但是可以降低肾小球滤过 率下降≥25%的风险(RR=0.91,95% CI:0.83=0.99 以及延缓肾小球滤过率下降(SMD=0.04,95% CI:0.02-0.07)。亚组分析显 示,在中度慢性肾脏病患者中,他汀类药物治疗对治疗前后肾小球滤过率变化这一指标有疗效(SMD=0.09,95% CI:0.04= 0.13)。阿托伐他汀(SMD=0.10,95% CI:0.03-0.17)及高强度降脂治疗(SMD=0.12,95% CI:0.02-0.21)对治疗前后肾小球滤过 率变化这一指标有效。结论尽管他汀类药物对降低终末期肾病发及肌酐翻倍的发生率无明显效果,但可以延缓肾小球滤过率 下降,其疗效与肾脏病分期、药物种类及降脂强度有关。
Abstract:
Objective Whether statins can slow down the progression of chronic kidney disease (CKD) remains controversial. We performed a meta-analysis to evaluate the effects of statin therapy on disease progression in adult patients with CKD who did not require dialysis therapy. Methods We searched the electronic databases for relevant randomized controlled trials (RCTs) published by February 2015. Random-effects meta-analysis of RCTs was used to pool the renal outcomes of the patients. Results Twenty-eight studies (30 RCTs) involving a total of 45 688 participants were included in the analysis. Compared with the control groups, statins produced no effects in preventing end-stage renal disease (ESRD) [relative risks (RR) 0.98, 95% confidence intervals (CI): 0.91-1.05] and in reducing the risk of doubling of the serum creatinine level (RR 1.43, 95% CI: 0.26-7.79). Statin therapy was associated with a lowered risk of estimated glomerular filtration rate (eGFR) reduction by 25% or more (RR 0.91, 95% CI: 0.83-0.99) and delayed the reduction of eGFR [standardized mean differences (SMD) 0.04, 95% CI: 0.02-0.07]. In subgroup analyses, the benefit of statins on changes in eGFR was statistically significant in patients with moderate CKD (SMD 0.09, 95% CI 0.04-0.13). Among different statins, atorvastatin was associated with a beneficial effect on kidney function (SMD 0.10, 95% CI 0.03-0.17). Patients who received high-intensity statin therapy showed significant changes in eGFR (SMD 0.12, 95% CI: 0.02-0.21). Conclusion Statin therapies may not prevent ESRD or doubling of serum creatinine level, but can improve GFR or delay the reduction of GFR in CKD patients. The therapeutic effects are associated with the patients’ baseline eGFR levels, statin types and therapy intensity.

相似文献/References:

[1]苏亮,白书昌,Bundhoo Kaviraj,等.8种eGFR估算方程评价心血管病患者肾小球滤过率的诊断价值比较[J].南方医科大学学报,2011,(07):1220.
[2]管玉青,石彦杰,王群.与他汀类药物和癫痫发作相关的横纹肌溶解症3例报告[J].南方医科大学学报,2011,(10):1795.
[3]王东,吴同茹,谢婷婷,等.中医辨证治疗慢性肾脏病蛋白尿的多中心前瞻性临床研究[J].南方医科大学学报,2013,(04):502.
[4]杨沿浪,邹和群,汪裕伟,等.两种肾小球滤过率评价公式评价健康体检人群慢性肾脏病患病率的对比研究[J].南方医科大学学报,2013,(09):1347.
[5]王贵佐,张永红,谢新明,等.他汀类药物与感染发生率及死亡率关系的meta分析[J].南方医科大学学报,2014,(07):988.
[6]肖倩蓉,范丽君,蒋薇,等.不同糖代谢状态人群慢性肾脏病的患病率及危险因素[J].南方医科大学学报,2016,(05):697.
[7]周琴,李永强,祝爽爽,等.非糖尿病人群腰臀比和慢性肾脏病的相关性[J].南方医科大学学报,2016,(09):1221.
[8]叶桂荣,周敏捷,于立新,等.肾移植受者、慢性肾脏病患者和健康对照者肠道菌群的对比[J].南方医科大学学报,2018,(12):1401.[doi:10.12122/j.issn.1673-4254.2018.12.01]
[9]刘华熙,吕智豪,田春阳,等.肾病Ⅲ号方治疗慢性肾脏病蛋白尿的机制:基于网络药理学方法[J].南方医科大学学报,2019,(02):227.[doi:10.12122/j.issn.1673-4254.2019.02.16]
[10]许伟成,黎池健,钱格,等.绝经前后代谢综合征与慢性肾脏病的相关性[J].南方医科大学学报,2019,(07):861.[doi:10.12122/j.issn.1673-4254.2019.07.18]

更新日期/Last Update: 1900-01-01